Varex Imaging Corporation (VREX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Financial performance is stable with strong cash management and expected revenue growth, but gross margins are impacted by tariffs. Product development in photon counting is promising but lacks immediate commercialization. Market strategy shows steady demand in China and a strong cargo systems pipeline, but lacks clarity in future guidance. Shareholder returns and debt repayment plans are positive, yet overall, the lack of clear guidance and tariff impacts balance the sentiment to neutral.
Key Financial Performance
Revenue Third quarter revenue was $203 million, down 3% year-over-year. The decrease was due to a 4% decline in the Medical segment, partially offset by a 1% increase in the Industrial segment. The decline in the Medical segment was attributed to paused shipments to Chinese customers earlier in the quarter due to high tariffs, which later resumed.
Non-GAAP Gross Margin Non-GAAP gross margin was 34%, up 100 basis points year-over-year. The increase was driven by a favorable product sales mix and lower-than-expected tariff-related expenses.
Non-GAAP Earnings Per Share (EPS) Non-GAAP EPS was $0.18, up $0.04 compared to the same quarter last year. This increase was attributed to improved gross margins and operational efficiencies.
Cash, Cash Equivalents, and Marketable Securities Ended the quarter with $153 million, down $73 million from the prior quarter. The decline was primarily due to the repayment of a $200 million convertible note.
Operating Income Operating income was $17 million, an increase of $2 million year-over-year. This was due to a decrease in operating expenses and improved gross margins.
Adjusted EBITDA Adjusted EBITDA for the quarter was $29 million, representing 14% of sales. This was supported by strong performance in the Industrial segment and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LUMEN HD and HD Pro digital radiography detectors: New competitively-priced family of detectors offering superior image quality, high reliability, fast image acquisition, lightweight design, and workflow improvement options. Regulatory licenses for the U.S. and Europe obtained, with production starting in Salt Lake City and planned for India by fiscal year-end.
THOR photon counting detector: Released for high-speed industrial CT imaging, targeting applications like EV batteries, semiconductor components, food, and material sorting. Designed for precision and high-speed imaging in demanding industrial applications.
India expansion: Plans to begin production of radiographic detectors in India by fiscal year-end to establish low-cost manufacturing for value-tier radiographic components, targeting competition from Asia-based companies.
Cargo inspection systems: Secured $17 million in new orders for international customers, bringing year-to-date bookings to over $55 million. Systems installed in countries like Saudi Arabia, Turkey, Colombia, and Bangladesh, with ongoing implementations in Brazil, Ukraine, Mexico, and Saudi Arabia.
Revenue performance: Third quarter revenue of $203 million exceeded guidance, with Industrial segment up 1% and Medical segment down 4% year-over-year. Non-GAAP gross margin improved to 34%, up 100 basis points from last year.
Debt reduction: Paid off $200 million convertible notes, reducing overall debt burden and simplifying capital structure.
Vertical integration in cargo systems: Developed systems integration capability in the U.K. and invested in U.S. facilities for component production and customer demonstration. Focused on innovation and cost-effectiveness in cargo inspection systems.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff-related challenges in China: Chinese customers paused shipments due to high tariffs (145%), which later dropped to 55%. This caused disruptions in delivery schedules and revenue flow.
Decline in Medical segment revenue: Medical segment revenue decreased by 4% year-over-year, impacting overall financial performance.
Non-cash goodwill impairment charge: A $94 million non-cash goodwill impairment charge was recorded due to a decline in the company's market capitalization, leading to a reported operating loss.
Inventory management challenges: Inventory levels increased by $14 million, with days of inventory rising to 201 days, indicating potential inefficiencies in inventory turnover.
Debt repayment impact on cash reserves: Repayment of $200 million convertible notes significantly reduced cash reserves by $73 million, potentially limiting financial flexibility.
Global trade environment uncertainties: The company operates in a challenging and constantly changing global trade environment, which could impact operations and strategic plans.
Fluoroscopy modality underperformance: Sales in the fluoroscopy modality were below the sales trend, indicating weaker demand in this area.
APAC revenue decline: Revenues in the APAC region decreased by 8% year-over-year, highlighting regional market challenges.
High operating expenses: Operating expenses were unusually high at $148 million, driven by the goodwill impairment charge, impacting profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Guidance for the fourth quarter is expected to be between $210 million and $230 million.
Earnings Per Share (EPS): Non-GAAP earnings per diluted share are expected to be between $0.10 and $0.30 of profit for the fourth quarter.
Gross Margin: Non-GAAP gross margin is expected to be between 32% and 33% for the fourth quarter.
Operating Expenses: Non-GAAP operating expenses are expected to be approximately $51 million for the fourth quarter.
Interest and Other Expenses: Interest and other expense net is expected to range between $9 million and $10 million for the fourth quarter.
Tax Rate: The tax rate is expected to be about 25% for the fourth quarter.
Diluted Share Count: Non-GAAP diluted share count is expected to be about 42 million shares for the fourth quarter.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Did fulfilling orders to China in the quarter result in higher than expected expenses?
A:No, fulfilling orders to China did not result in higher than normal expenses. The company had the capacity to meet the demand.
Q:Do you expect China sales in the fourth quarter to be on par with Q3 or possibly start to tick up?
A:The company does not provide guidance by region or customer, but overall demand in China is stable and healthy, and is expected to remain normal barring any external events.
Q:Do you have any of your medical OEMs testing the photon counting technology?
A:Yes, the big CT projects are on the medical side, and the company has ongoing activity in several industrial applications. However, the primary focus and investment in photon counting is for medical CT.
Q:What is the plan for paying down debt going forward?
A:The company plans to continue building its cash position to target gross debt in the $300 million to $350 million range. They aim to address refinancing needs before the next tranche, which is about 2 years away.
Q:Is the guidance for $9 million to $10 million of interest expense for the fourth quarter net of any interest income?
A:Yes, the guidance is net of interest income and other operating and expense items.
Q:Can you characterize the capital spending environment and its sustainability in the medical side of the business going into fiscal '26?
A:The environment appears healthy with good demand patterns. Hospital CapEx, imaging investment priorities, and procedure volumes are in a decent place. FY '24 was soft due to inventory destocking, but FY '26 is expected to start in a decent macro demand environment.
Q:Where are you seeing strength within the Medical segment that is leading to better revenue numbers?
A:The Industrial business and CT were strong in the last quarter. Radiographic was stable, while fluoroscopy was down. Strength was observed in CT and Industrial.
Q:Can you provide metrics or timelines for photon counting commercialization?
A:The company expects $150 million in photon counting revenue by 2029, with $100 million from Medical and $50 million from Industrial. Currently, most shipments are in Industrial, and Medical is expected to grow in a stepwise manner. Two OEMs are actively developing systems, with commercialization expected beyond the next 12 months.
Q:What are your expectations for potential outsized orders in China and the impact of government stimulus?
A:Order intake from China has been steady, with no lumpy buying behavior or significant impact from government stimulus observed. The Chinese government remains committed to expanding healthcare services, which supports steady demand for CTs.
Q:Is the ramping up of system production in the U.K. and investment in the Vegas facility a signal for more outsized orders in the cargo systems business?
A:The U.K. expansion is to fulfill existing orders, and the pipeline for cargo systems is strong. Order sizes of $17 million to $25 million are not uncommon, and the company is preparing to compete and fulfill such orders.
Q:What is driving the sequential and year-over-year growth in Q4 guidance?
A:Both Medical and Industrial segments are expected to grow in Q4. Industrial growth is driven by cargo systems orders, while Medical growth is supported by backlog fulfillment in Japan and Europe.
Q:Why is the gross margin outlook lower despite sequential growth in Q4?
A:The lower gross margin is due to tariff impacts, lower margins in the cargo systems business, and a mix shift. The company is addressing these through price increases and supply chain adjustments.
Q:What is the outlook for fiscal '26 growth?
A:Fiscal '26 is expected to be a growth year, with inventory destocking completed and China stabilizing. Both Medical and Industrial businesses are in a decent position, barring unforeseen external events.
Q:What progress has been made in redirecting supply chains to mitigate tariff exposure?
A:Good progress has been made, including production in India, bonded warehouses, and local-for-local manufacturing. However, these initiatives are still in midstream and will take time to fully implement.
Q:Will shipping detectors from the India plant by year-end impact tariff exposure in China?
A:The India plant primarily focuses on cost-effective radiographic component production for global consumption. Detectors for China are already supported by local manufacturing, so the impact on tariff exposure in China is minimal.
Q:Is there any connection between the India plant and U.S. production that might be affected by trade tensions?
A:There is minimal dependence of U.S. production on the India plant. The company has diversified its supply chain to ensure resiliency.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or metrics for photon counting commercialization, citing confidentiality and customer privacy. They also did not provide detailed guidance for fiscal '26, only indicating a general expectation of growth. Additionally, they did not quantify the impact of government stimulus in China, stating it is hard to separate from normal demand.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Belfiore
Inc Research
LLC
LUMEN HD
Research Division
Saudi Arabia
Securities Inc
THOR
UK
application
capability
cargo system
component
cost
design option
emergency
employee
energy
facility
factory India
image acquisition
inspection industry
inspection system
integration
legacy
line sale
note
product line
project
prospect
quality
radiography
ray
tariff
team
trend sale
use
VREX Transcript
Varex Imaging Corporation (VREX) Q2 2026 Earnings Call Transcript
Positive5-7
The earnings call showed strong financial performance with a 5% revenue increase and improved gross margins. EPS also grew to $0.50, indicating robust profitability. The medical imaging segment's demand supports future growth. Although operating expenses rose, they were tied to R&D investments, which could drive innovation. No strategic initiatives or risks were discussed, leaving a neutral impact. Overall, the financial results and EPS improvement suggest a positive stock price movement.
Varex Imaging Corporation (VREX) Q1 2026 Earnings Call Transcript
Positive2-11
The earnings call summary reveals strong financial performance with increased operating income and adjusted EBITDA. The Q&A section highlights optimism in the market outlook and potential double-digit growth in the Industrial segment. The India expansion and photon counting technology are promising, despite some inventory challenges. The cautious EPS guidance is offset by strong CT adoption and customer engagement. Overall, the sentiment is positive, likely resulting in a 2% to 8% stock price increase.
Varex Imaging Corporation (VREX) Q4 2025 Earnings Call Transcript
Unknown11-18
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
Varex Imaging Corporation (VREX) Q3 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed picture. Financial performance is stable with strong cash management and expected revenue growth, but gross margins are impacted by tariffs. Product development in photon counting is promising but lacks immediate commercialization. Market strategy shows steady demand in China and a strong cargo systems pipeline, but lacks clarity in future guidance. Shareholder returns and debt repayment plans are positive, yet overall, the lack of clear guidance and tariff impacts balance the sentiment to neutral.
VREX Slides
VREX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
